Multiple Myeloma Innovative Therapy

Multiple Myeloma Research Center

The following are the Research Protocols for the different Management stages of Multiple Myeloma

Newly Diagnosed

Doxil, Vincristine, Decadron, and Thalidomide. This is a trial that evaluates the role of thalidomide in improving response rate as well as the quality of response to DVd
Doxil, Vincristine and Decadron (DVd) vs. VAD in newly diagnosed myeloma Phase III Trial in Newly Diagnosed Multiple Myeloma patients. this study is to confirm the results of the phase II DVd trial performed at our institutions

Refractory/Relapsed

Phase II Study of Arsenic Trioxide in Patients with Multiple Myeloma

Doxil, Vincristine, Decadron, and Thalidomide this study is designed to evaluate the role of Thalidomide in increasing the response rate to DVd

Cycling Myeloma cells with rHu GM-CSF Phase II trial to treat Multiple Myeloma patients with Cytoxan and Vincristine after, Followed by GM-CSF Maintenance.

Phase II study of PS-341 alone or in combination with Dexamethasone this is a study for patients with Multiple Myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy. there are no limits to the number of previous therapies.

Neovestat (Shark Cartilage) this is a limited patient population study. Only patients who have failed one regimen, followed by a salvage that did not result in a greater than 50% decrease in proteins

Genasense (anti-BCL-2) this is a phase III trial comparing single agent Decadron to anti-bcl-2 therapy. There is no cross over to the active treatment arm.

Maintenance

GM-CSF Maintenance following VAD Treatment. A Phase II study
A Phase II efficacy, tolerability, and safety study of Vincristine, Doxorubicin, Dexamethasone, and SDZ PSC 833 therapy in-patients with VAD Refractory Multiple Myeloma. ( Closed, possible improvement in response rate)
High dose Intermittent Schedule ATRA Phase II trial to evaluating its role of in the Management of Multiple Myeloma. (Closed, responses were short lived, however resulted in disease stabilization for an average of 4 months)
IL-2 Maintenance Therapy Pilot study to evaluate following chemotherapy with VAD for multiple Myeloma. (Closed, awaiting data maturation)

Supportive Care

Less Frequent Procrit Dosing in Multiple Myeloma
Osteoprotegerin (OPG)
Zoledronate Protocol completed (Closed, available data support a role for Zometa in the management of multiple myeloma. At 13 months, Zometa is not inferior to Aredia, and theoretically over the long run it could possibly be better)

This page was last updated on 09/08/2003 05:51:25 PM



Questions, Suggestions or to Enquire about a trial
Phone: 216-445-6830 Fax: 216-445-3434

Maps & Directions

Page Last Updated 09/08/2003 05:51:25 PM